These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8038709)

  • 61. Deletion mutants of human interleukin 1 beta with significantly reduced agonist properties: search for the agonist/antagonist switch in ligands to the interleukin 1 receptors.
    Simoncsits A; Bristulf J; Tjörnhammar ML; Cserzö M; Pongor S; Rybakina E; Gatti S; Bartfai T
    Cytokine; 1994 Mar; 6(2):206-14. PubMed ID: 8032002
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interleukin-1 receptor antagonist as therapy for inflammatory disorders.
    Freeman BD; Buchman TG
    Expert Opin Biol Ther; 2001 Mar; 1(2):301-8. PubMed ID: 11727537
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinants.
    Nicod LP; el Habre F; Dayer JM
    Cytokine; 1992 Jan; 4(1):29-35. PubMed ID: 1535518
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.
    Cunnane G; Madigan A; Murphy E; FitzGerald O; Bresnihan B
    Rheumatology (Oxford); 2001 Jan; 40(1):62-9. PubMed ID: 11157143
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.
    Symons JA; Young PR; Duff GW
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1714-8. PubMed ID: 7878046
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A urine inhibitor of interleukin 1 activity that blocks ligand binding.
    Seckinger P; Lowenthal JW; Williamson K; Dayer JM; MacDonald HR
    J Immunol; 1987 Sep; 139(5):1546-9. PubMed ID: 2957429
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alternative views on the effects of recombinant interleukin-1-receptor antagonist.
    Vance-Bryan K; Hoey LL; Joslin SM
    Am J Hosp Pharm; 1994 Nov; 51(21):2724-7. PubMed ID: 7710539
    [No Abstract]   [Full Text] [Related]  

  • 68. Administration of recombinant human interleukin 1 receptor antagonist during endotoxin-induced mastitis in cows.
    Shuster DE; Kehrli ME
    Am J Vet Res; 1995 Mar; 56(3):313-20. PubMed ID: 7771698
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regulation of peptide-chain initiation in muscle during sepsis by interleukin-1 receptor antagonist.
    Vary TC; Voisin L; Cooney RN
    Am J Physiol; 1996 Sep; 271(3 Pt 1):E513-20. PubMed ID: 8843745
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis.
    Slotman GJ; Quinn JV; Wry PC; Brathwaite CE; Friedman BM
    Ann Surg; 1997 Jul; 226(1):77-84. PubMed ID: 9242341
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta.
    Evans RJ; Bray J; Childs JD; Vigers GP; Brandhuber BJ; Skalicky JJ; Thompson RC; Eisenberg SP
    J Biol Chem; 1995 May; 270(19):11477-83. PubMed ID: 7744786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B
    BioDrugs; 2001; 15(2):87-97. PubMed ID: 11437678
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interleukin-1 receptor antagonist.
    Lennard AC
    Crit Rev Immunol; 1995; 15(1):77-105. PubMed ID: 8519423
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular cloning and functional expression of equine interleukin-1 receptor antagonist.
    Kato H; Ohashi T; Matsushiro H; Watari T; Goitsuka R; Tsujimoto H; Hasegawa A
    Vet Immunol Immunopathol; 1997 May; 56(3-4):221-31. PubMed ID: 9223227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The balance between IL-1 and IL-1Ra in disease.
    Arend WP
    Cytokine Growth Factor Rev; 2002; 13(4-5):323-40. PubMed ID: 12220547
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulation of IL-1 activity by soluble IL-1 receptors.
    Kurrle R; Lauffer L; Röder J; Kanzy EJ; Enssle KH; Seiler FR
    Behring Inst Mitt; 1995 Jun; (96):45-57. PubMed ID: 7575352
    [No Abstract]   [Full Text] [Related]  

  • 77. Interaction of recombinant monocyte-derived interleukin 1 receptor antagonist with rheumatoid synovial cells.
    Arend WP; Coll BP
    Cytokine; 1991 Sep; 3(5):407-13. PubMed ID: 1836395
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I.
    Svenson M; Hansen MB; Heegaard P; Abell K; Bendtzen K
    Cytokine; 1993 Sep; 5(5):427-35. PubMed ID: 8142597
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of rheumatoid arthritis with IL-1 inhibitors.
    Gabay C; Arend WP
    Springer Semin Immunopathol; 1998; 20(1-2):229-46. PubMed ID: 9836379
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra.
    Muzio M; Polentarutti N; Facchetti F; Peri G; Doni A; Sironi M; Transidico P; Salmona M; Introna M; Mantovani A
    Eur J Immunol; 1999 Mar; 29(3):781-8. PubMed ID: 10092080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.